H.C. Wainwright expects Sensus Healthcare to see strong 2022 growth

Sensus Healthcare

14/02/2022 16:54

** Shares of medical device maker  SRTS.O  rise 11% to $9.04
    ** H.C. Wainwright lifts PT on SRTS to $12 from $10 after
company reported record Q4 results last week; new PT represents
a 47% upside to stock's last close
    ** SRTS, which sells radiation devices to treat skin
cancers, during its conference call noted strong backlog of
orders coming into the new year
    ** "In our view, order backlog indicates strong market
demand, which could persist in 2022 as patient visits to
dermatologists' offices have returned to and exceeded the
pre-pandemic levels," says H.C. Wainwright
    ** Says the hit from the pandemic is over for SRTS and it
expects continuous top- and bottom-line growth in 2022
    ** Brokerage is also optimistic about co's deal to
exclusively market Mattioli Eng. Italia  S.P.A.'s FDA-cleared
device in the U.S. for needle-free delivery of fillers and other
injectables
    ** The device is a "clear competitive advantage in the
aesthetic dermatology space" and could boost company's revenue
this year - H.C. Wainwright
    ** SRTS rose 87% in 2021

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))